جامعة المعرفة
المصدر المعتمد للمعلومات البحثية والمخرجات هو قاعدة بيانات سكوبس (Elsevier Scopus) مع تدقيق بيانات الباحثين من عمادة البحث العلمي.

Research outputs

المخرجات البحثية

مقالات ومراجعات وأوراق مؤتمرات وفصول كتب، مفهرسة برقم DOI ومربوطة بباحثي الجامعة.

31 مُخرَج نتائج البحث عن «Cochrane Library»

مراجعةمفتوح (مستودع)20266استشهاد· Semantic Scholar

Perioperative outcomes and safety of Uniportal Robotic-Assisted Thoracic Surgery (U-RATS) for anatomic lung resection: a systematic review and meta-analysis

Journal of Robotic Surgery · مجلد 20 (1)

Uniportal robotic-assisted thoracic surgery (U-RATS) represents a recent evolution in minimally invasive lung resection, combining the single-incision philosophy with robotic technology. However, its perioperative safety and outcomes have not been clearly defined across published studies. A systematic review and meta-analysis were conducted in accordance with PRISMA guidelines and a registered protocol. PubMed, Web of Science, and the Cochrane Library were searched for studies reporting perioperative outcomes of U-RATS for anatomic lung resection in adults. Primary outcomes included conversion rate, morbidity, and mortality. Secondary outcomes were operative time, estimated blood loss, length of hospital stay, and lymph node yield. Random-effects models were applied to pool estimates. Sixteen studies encompassing 579 patients were included. The pooled conversion rate was 1.34% (95% CI: 0.42–4.15%), with no observed heterogeneity. The pooled postoperative morbidity rate was 5.99% (95% CI: 4.46–7.91%), and the pooled mortality rate was 0.21% (95% CI: 0.07–0.64%). The pooled mean operative time was 171.3 min, the estimated blood loss was 51.9 mL, and the postoperative length of stay was 4.9 days. Across 11 studies, the pooled lymph node yield was 16.6 nodes (95% CI: 14.0–19.2; I² = 89.8%). Current evidence suggests that U-RATS is a safe and feasible approach for anatomic lung resection, with low conversion and complication rates and acceptable perioperative outcomes comparable to established minimally invasive techniques.

anatomical lung resectionperioperative outcomesconversion ratepostoperative morbidity
مراجعةوصول مفتوح20262استشهاد· Semantic Scholar

Efficacy and Safety of Laser-Based Therapies for Melasma: A Systematic Review and Meta-Analysis

Cureus · مجلد 18 (3) · e106154-e106154

Melasma is a chronic acquired hyperpigmentation disorder that often exerts a psychosocial burden on affected individuals. Although laser- and light-based therapies are pivotal third-line interventions for recalcitrant cases, clinical consensus regarding their comparative efficacy and long-term safety remains inconsistent. This systematic review and meta-analysis aimed to evaluate and synthesize evidence from randomized controlled trials (RCTs) on the efficacy and safety of various laser-based therapies for melasma. A literature search was performed using PubMed, Excerpta Medica Database (EMBASE), Cochrane Library, and Web of Science databases from inception to January 2026. RCTs and split-face comparative studies evaluating laser therapies versus placebo, topical agents, or alternative laser modalities were included. Data synthesis was performed using a random-effects model with Hartung-Knapp adjustment. The primary outcome was the mean difference (MD) in the reduction of the Melasma Area and Severity Index (MASI) score. The certainty of evidence was appraised using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. Fifty-two studies, involving 1,058 participants, met the inclusion criteria. The overall pooled analysis showed a trend toward clinical improvement that was not statistically significant (MD: 0.70; 95% CI: -0.55, 1.95; p = 0.2682). Subgroup analysis by laser technology revealed that low-fluence Q-switched Nd:YAG (QSNY) (1064 nm) lasers provided a statistically significant reduction in melasma severity (MD 1.47; 95% CI: 0.08 to 2.85, p < 0.05), while picosecond lasers (MD -0.11; 95% CI: -0.79 to 0.57) and fractional lasers (MD 0.94; 95% CI: -0.84 to 2.71) did not significantly outperform control groups. Statistical heterogeneity was high across the evidence (I² = 96.2%). The overall certainty of evidence for the primary outcome was very low because of the lack of blinding and the high inconsistency. No serious adverse events were reported, although minor complications, such as transient erythema and localized burning, were common. Low-fluence QSNY laser therapy is an effective adjunctive modality for melasma management. However, due to high recurrence rates and variability in outcomes, it should be integrated into a multi-modal approach alongside strict photoprotection and topical depigmenting agents. Future research should prioritize the long-term follow-up and standardization of laser parameters across different skin phenotypes.

melasmalaser therapyQ-switched Nd:YAG laserpicosecond laser
مراجعةوصول مفتوح20261استشهاد· Semantic Scholar

Single level versus multi-level lumbar interbody fusion for lumbar degenerative diseases: a systematic review and meta analysis

Journal of Orthopaedic Surgery and Research · مجلد 21 (1)

BACKGROUND: Degenerative spondylolisthesis affects approximately 39 million patients worldwide. While consensus supports decompression with fusion for single-level pathology, optimal surgical approaches for multi-level disease remain disputed. Despite the frequency of this clinical presentation, evidence comparing outcomes between Single-Level versus Multi-Level interbody fusion procedures is surprisingly scarce. This study aims to determine how the level of interbody fusion extent impacts outcomes in patients undergoing lumbar fusion for degenerative spondylolisthesis. METHODS: Our systematic review methodology involved comprehensive database searches (Web of Science, Scopus, PubMed, and Cochrane Library) from inception through April 2025. Two independent reviewers performed article screening, data extraction, and quality assessment. Statistical analyses used R software (v4.4.2), with outcomes reported as risk ratios for categorical variables and mean differences for continuous measures (95% CI). The certainty of evidence was assessed using the GRADE approach. RESULTS: Our meta-analysis evaluated 10 studies (N = 1430 patients; 971 Single-Level, 366 Double-Level, 198 Multi-Level fusions). Single-Level procedures demonstrated 41% lower revision rates (RR = 0.59 [0.40-0.86], p = 0.007). Operative advantages included reduced surgical time (-60.73 min [- 80.89 to - 40.57], p < 0.001), blood loss (-286.99mL [- 496.71 to - 77.27], p = 0.007), and hospitalization (-1.22 days [- 2.09 to - 0.34], p = 0.006). Oswestry Disability Index (ODI) scores showed borderline improvement (-3.90 [- 7.89 to 0.10], p = 0.06). Screw loosening decreased by 84% (RR = 0.16 [0.08-0.34], p < 0.001). We observed no significant differences in lumbar lordosis (-0.01 [- 1.75 to 1.72], p = 0.99), infection rates (RR = 0.49 [0.19-1.25], p = 0.13), adjacent segment deterioration, vascular injuries, or dural tears. The certainty of evidence ranged from low to very low, and high heterogeneity was observed in perioperative outcomes. CONCLUSIONS: Single-level fusion may offer a more favorable perioperative profile than double- or multi-level constructs, including lower revision risk, shorter operative time, reduced blood loss, shorter hospitalization, and fewer screw loosening events in pooled analyses. However, complications did not differ significantly between groups. Given substantial heterogeneity for perioperative outcomes and generally low to very low certainty of evidence, these findings should be interpreted cautiously and individualized to patient pathology and surgical context.

lumbar interbody fusiondegenerative spondylolisthesismultilevel fusionsingle-level fusion
مراجعةوصول مفتوح20261استشهاد· Semantic Scholar

Association Between Maternal C-Reactive Protein (CRP) Levels and Adverse Neonatal Outcomes: A Systematic Review and Meta-Analysis

Journal of Clinical Medicine · مجلد 15 (6) · 2114-2114

Background: C-reactive protein (CRP), a biomarker of systemic inflammation, has been implicated in adverse pregnancy and neonatal outcomes. However, the relationship between maternal CRP and neonatal complications remains unclear. We conducted a systematic review and meta-analysis to synthesize available evidence. Methods: We systematically searched PubMed, Scopus, Web of Science, and Cochrane Library up to July 2025 for observational studies reporting maternal CRP levels in relation to neonatal outcomes. Eligible outcomes included preterm birth (PTB), low birth weight (LBW), small for gestational age (SGA), and stillbirth. Random-effects models were used to calculate pooled standardized mean differences (SMD) or odds ratios (OR) with 95% confidence intervals (CI). Statistical heterogeneity was assessed using the I2 statistic. Results: The search yielded 6843 records, of which 42 studies (comprising 18,393 pregnant women) met the inclusion criteria. Maternal mean CRP levels were significantly higher in adverse pregnancy outcomes compared with controls (SMD = 0.39; 95% CI 0.08–0.70; p = 0.01; I2 = 96.6%). Elevated CRP was strongly associated with PTB (OR = 3.81; 95% CI 2.66–5.47; p < 0.001; I2 = 85%; n = 23) and LBW (OR = 2.34; 95% CI 1.35–4.03; p = 0.002; I2 = 84.2%; n = 7). No significant associations were observed for SGA (OR = 1.14; 95% CI 0.86–1.49; p = 0.36; I2 = 0%; n = 5) or stillbirth (OR = 1.89; 95% CI 0.92–3.90; p = 0.08; I2 = 44.9%; n = 4). Conclusion: Maternal CRP is significantly associated with increased risks of preterm birth and low birth weight but not with SGA or stillbirth. These findings support the role of systemic inflammation in adverse neonatal outcomes and highlight the need for prospective studies to clarify causal mechanisms and assess the clinical utility of CRP in pregnancy risk stratification.

C-reactive proteinmaternal inflammationpreterm birthlow birth weight
مراجعةمفتوح (مستودع)2026

Comparative Efficacy and Safety of Intranasal Opioids versus Intravenous Morphine for Acute Moderate-to-Severe Pain: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Journal of Emergency Medicine

Background Intranasal (IN) opioids may provide non-invasive analgesia without delays associated with intravenous (IV) access, but their efficacy and safety versus IV morphine remain uncertain. Objectives To synthesize randomized evidence comparing IN opioids with IV morphine for acute moderate-to-severe pain. Methods PubMed, Scopus, Web of Science, and the Cochrane Library were searched from inception to May 2026 for randomized controlled trials (RCTs) in adults or children with acute moderate-to-severe pain in emergency, prehospital, procedural, or postoperative settings. Eligible trials directly compared IN opioids with IV morphine. The primary outcome was change in pain score from baseline at 20 and 30 minutes. Secondary outcomes included rescue analgesia and adverse events. Outcomes were pooled as standardized mean differences (SMD) or risk ratios (RR) using random-effects models. Results Ten RCTs involving 1,164 participants were included. IN opioids showed comparable analgesic efficacy to IV morphine at 20 minutes (SMD = −0.05, 95% CI: −0.24 to 0.14; p = 0.59; I² = 11.94%) and 30 minutes (SMD = −0.05, 95% CI: −0.24 to 0.15; p = 0.64; I² = 0.00%). Rescue analgesia was comparable (RR = 1.00, 95% CI: 0.81 to 1.25; p = 0.98). No significant differences were observed in overall adverse events, serious adverse events, respiratory complications, hypotension, gastrointestinal events, dizziness, or rhinorrhea. Dysgeusia was borderline increased. Conclusion IN opioids provide analgesic efficacy comparable to IV morphine at 20 and 30 minutes, with no clear increase in systemic adverse events. Larger trials should confirm safety for rare serious events and optimize dosing.

intravenous morphineanalgesic efficacyadverse eventsrescue analgesia
مراجعةوصول مفتوح2026

The Impact of Preexisting Cardiac Implantable Electronic Devices on the Safety of Transcatheter Tricuspid Valve Interventions: A Systematic Review and Meta-Analysis

Journal of Cardiovascular Development and Disease · مجلد 13 (10) · 478-478

Background: Tricuspid regurgitation (TR) increases mortality but remains undertreated due to high surgical risks. Transcatheter tricuspid valve interventions (TTVI) offer safer alternatives, improving functional status and quality of life. However, many candidates for TTVI have trans-tricuspid CIED leads that may interfere with procedural imaging and device deployment and may be exposed to dislodgement, entrapment, or jailing. Evidence regarding both clinical outcomes and postprocedural CIED function in this population remains limited. Existing trial evidence for this population is scarce, requiring further safety analysis. To our knowledge, this is the first meta-analysis to address the comparative risk of complications and residual TR in patients with vs. without CIEDs. Methods: We searched for relevant articles up to March 2026 from PubMed, Scopus, Cochrane Library, and Web of Science. Two independent reviewers extracted data from the selected studies, including baseline information, outcomes, comorbidities, hospitalization metrics, TR severity, and complications. All data analyses were performed using R version 4.4.1. Results: Ten studies comprising 5415 patients were included. Nine comparative studies contributed to the quantitative synthesis, whereas one single-arm study contributed only to the narrative synthesis of CIED-specific mechanical and electrical outcomes. In patients undergoing TTVI, across two studies, patients with CIEDs had a nominally lower risk of single-leaflet device attachment (RR 0.34, 95% CI 0.12–0.94; nominal p = 0.037); however, this exploratory finding should be considered hypothesis-generating. However, no statistically significant differences were observed between groups for cardiovascular death (RR 1.30, p = 0.815), device embolization (RR 1.62, p = 0.666), device malposition (RR 1.10, p = 0.909), stroke (RR 0.52, p = 0.335), hospitalization for heart failure (RR 1.02, p = 0.931), in-hospital mortality (RR 1.02, p = 0.959), major adverse events (RR 0.74, p = 0.635), major bleeding (RR 0.70, p = 0.187), or residual tricuspid regurgitation of mild (RR 0.98, p = 0.686) or moderate severity (RR 1.01, p = 0.646). CIED-specific outcomes were reported heterogeneously. Lead function was generally preserved after T-TEER in carefully selected patients, whereas studies of TTVR with jailed leads reported lead failure or malfunction ranging from 5.8% to 21% in individual cohorts. Conclusions: Among the comparative outcomes available for quantitative pooling, no statistically significant differences were detected between patients with and without CIEDs for most procedural and postprocedural outcomes. However, CIED-specific risks differed according to the intervention. Lead function was generally preserved after T-TEER in carefully selected patients, whereas lead jailing during TTVR was associated with clinically relevant lead malfunction in some cohorts. Therefore, the absence of significant differences in pooled clinical outcomes should not be interpreted as evidence that TTVI does not affect CIED function.

transcatheter tricuspid valve interventiontricuspid regurgitationcardiac implantable electronic devicesdevice embolization
ملخص مؤتمروصول مفتوح2026

Diagnostic Accuracy of Modalities For Acute Heart Failure In Emergency Settings. A Systematic Review and Diagnostic Accuracy Meta-Analysis

Saudi Journal of Emergency Medicine · مجلد 7 (1S) · 91-91

Background: Acute heart failure diagnosis in emergency departments remains challenging despite multiple available diagnostic modalities. Current emergency evaluations rely variably on clinical assessment, biomarkers, and ultrasound techniques; however, their comparative diagnostic accuracy remains inadequately compared in previous studies. This systematic review and meta-analysis aim to evaluate the diagnostic accuracy of four categories of diagnostic approaches: Clinical Assessment, Biomarker Assessment, Basic Ultrasound Assessment, and Advanced Ultrasound Assessment for diagnosing acute heart failure in emergency settings. Methods: We conducted a literature review across PubMed/MEDLINE, Scopus, Google Scholar, Cochrane Library, Google Scholar, and Web of Science up to December 2024. Studies investigating the diagnostic modalities for acute heart failure in emergency settings with sufficient data to construct 2×2 contingency tables were included. Two independent reviewers performed screening, data extraction, and quality assessment using QUADAS-2. Diagnostic accuracy was synthesized using a bivariate random-effects model. Summary receiver operating characteristic (SROC) curves, pooled sensitivity, specificity, and area under the curve (AUC) were calculated with 95% confidence intervals (CI). Heterogeneity was assessed using I² statistics and publication bias with Deeks' funnel plot. Results: Thirty-three studies including a total of 17 participants to 1,586 participants met the inclusion criteria. Clinical Assessment demonstrated moderate diagnostic performance (AUC=0.591) with limited sensitivity (0.500, 95% CI: 0.484-0.515) but high specificity (0.858, 95% CI: 0.830-0.886). Biomarker Assessment showed excellent performance (AUC=0.906) with high sensitivity (0.874, 95% CI: 0.872-0.875) and good specificity (0.781, 95% CI: 0.778-0.783). Basic Ultrasound Assessment had moderate performance (AUC=0.750) with low sensitivity (0.349, 95% CI: 0.303-0.395) but high specificity (0.889, 95% CI: 0.874-0.904). Advanced Ultrasound Assessment demonstrated excellent performance (AUC=0.892) with good sensitivity (0.713, 95% CI: 0.705-0.720) and very high specificity (0.903, 95% CI: 0.900-0.905). All modalities showed remarkably consistent performance across studies (I²=0%). Conclusion: Biomarker Assessment provides the highest overall diagnostic accuracy for acute heart failure in emergency settings, while Advanced Ultrasound Assessment offers the optimal balance between sensitivity and specificity when equipment and expertise are available. Clinical Assessment alone has limitations for detecting acute heart failure but remains useful for exclusion. Our findings highly recommend adapting a multimodal diagnostic approach integrating biomarkers and advanced ultrasound techniques whenever possible for optimal diagnostic accuracy in emergency settings.

acute heart failureemergency diagnosisdiagnostic accuracyclinical evaluation
مراجعةوصول مفتوح2026

Hepatoprotective effects of empagliflozin in metabolic dysfunction-associated steatotic liver disease: a systematic review and meta-analysis of preclinical studies

Frontiers in Pharmacology · مجلد 17 · 1822157-1822157

Background: The worldwide burden of metabolic dysfunction-associated steatotic liver disease (MASLD) is rising sharply, powered by high prevalence of obesity and its associated metabolic insults. Though urgent, definitive treatment is not yet available. Empagliflozin, a sodium glucose co-transporter inhibitor has been suggested in both human and animal studies to have diverse beneficial effects in MASLD by anti-inflammation and anti-oxidative stress effects, but many of the underlying mechanisms remain unexplained. The main aim of this systematic review and meta-analysis was to evaluate the effects of empagliflozin's in preclinical animal studies trying to view new horizons for future treatment of MASLD. Methods: we searched the related animal preclinical studies in databases including Scopus, Web of Science, Cochrane library, Wily online library and PubMed. The research team screened the literature and extracted data; any discrepancies were resolved by the research team leader through discussion. The quality of research methods was assessed by SYRCLE (systematic review center for laboratory animal experimentation) risk of bias tool. The meta-analysis was guided by the Cochrane Handbook; statistical analyses were conducted via RevMan 5.4 offline version and Comprehensive Met analysis V3 software. Results: Our meta-analysis included 17 studies, involving 584 animals. In comparison with the model group, empagliflozin significantly reduced steatosis markers including hepatic burden of lipids, including triglycerides and cholesterol, NAFLD Activity Score (NAS) and total serum cholesterol (TC). It also significantly reduced hepatic fibrosis markers including fibrosis grade, transforming growth factor-β (TGF-β) and collagen type I alpha 1 chain) COL1A1). Beyond its anti-steatofibrotic effects, empagliflozin significantly downregulated hepatic expression of inflammatory and oxidative markers including tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6) and malondialdehyde (MDA). Moreover, empagliflozin significantly improved glycemic indices including Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), serum insulin, and fasting blood sugar (FBS). Conclusion: Empagliflozin significantly protected the liver against steatosis and fibrosis by mitigating hepatic inflammation, oxidative stress and insulin resistance.

empagliflozinnon-alcoholic fatty liver diseaseSGLT2 inhibitorshepatic steatosis
مراجعةوصول مفتوح2026

Clinical utility of artificial intelligence in prehospital emergency medical services : a systematic review and meta-analysis

Universa Medicina · مجلد 45 (2) · 294-309

BackgroundThe emergency medical services (EMS) sector presents substantial hurdles in providing excellent treatment while operating within limited resources. Artificial intelligence (AI) has significant potential in prehospital EMS, where rapid and accurate decision-making is essential. However, a comprehensive synthesis of AI’s effectiveness in this setting remains limited. The objective of this systematic review and meta-analysis was to evaluate AI’s predictive accuracy, compare its performance with human-based triage, and assess its feasibility in prehospital care. MethodsFollowing PRISMA guidelines, PubMed, Cochrane Library, and Web of Science were searched up to February 20, 2025. Fourteen peer-reviewed studies reporting quantitative outcomes were included. Study quality was assessed using the Newcastle-Ottawa Scale (median score = 7). Random-effects meta-analyses in R were conducted to synthesize area under the curve (AUC), AI-human AUC differences, and feasibility outcomes. ResultsAcross 14 studies involving 9,107,906 patients, AI demonstrated strong predictive performance with a pooled AUC of 0.874 (95% CI: 0.843–0.905). Individual study AUCs ranged from 0.805 to 0.997, with moderate heterogeneity (I²=52.3%). In eight studies, AI significantly outperformed human triage, showing a pooled AUC improvement of 0.074 (95% CI: 0.045–0.103; p<0.001), despite high heterogeneity due to varying human benchmarks. Feasibility analysis showed high clinical utility, with a pooled proportion of 0.929 and no heterogeneity (I²=0%). Funnel plots suggested slight asymmetry, but Egger’s tests indicated no significant publication bias. ConclusionArtificial intelligence demonstrated high predictive accuracy, slight superiority over human triage, and strong feasibility in prehospital care, supporting its integration into EMS with further validation and standardized reporting.

artificial intelligenceprehospital emergency medical servicesemergency medical triageprediction accuracy
مراجعةوصول مفتوح2026

Efficacy and safety of azithromycin in preventing bronchopulmonary dysplasia in preterm infants: a systematic review and meta-analysis

Frontiers in Pediatrics · مجلد 14 · 1780809-1780809

Introduction Ureaplasma colonization in preterm infants is linked to pulmonary inflammation and bronchopulmonary dysplasia (BPD). Evidence regarding the effectiveness of macrolides, including their prophylactic role in preventing BPD, remains limited. This review aimed to assess whether azithromycin reduces the incidence of BPD or death in preterm infants, with or without Ureaplasma colonization, compared with placebo or no intervention. Methods We followed PRISMA guidelines and searched PubMed, Cochrane Library, Embase, and Google Scholar for randomized controlled trials (RCTs) evaluating azithromycin in preterm infants with unknown or confirmed Ureaplasma infection. Primary outcomes were death and BPD, while secondary outcomes included hospital stay, adverse events, and ventilation or oxygen duration. Studies not focused on preterm infants, lacking Ureaplasma status, or not randomized were excluded. Results A meta-analysis of six randomized controlled trials, including 1,446 preterm infants with unknown or confirmed Ureaplasma status and sample sizes ranging from 80 to 796, compared azithromycin with placebo. No significant reduction was observed in BPD incidence [risk ratio (RR) = 0.92, 95% CI: 0.78–1.09, p = 0.35] or mortality (RR = 0.88, 95% CI: 0.66–1.18, p = 0.39). Heterogeneity was low for mortality ( I 2 = 0%) and moderate for BPD ( I 2 = 61%). Secondary outcomes showed no significant differences in mechanical ventilation days (mean difference=0.07, 95% CI: −0.78 to 0.33, p = 0.58), supplemental oxygen requirement (mean difference=−0.45, 95% CI: −0.98 to 0.07, p = 0.09), or hospitalization duration (mean difference=−0.02, 95% CI: −0.19 to 0.15, p = 0.85). Heterogeneity ( I 2 ) was 94% for supplemental oxygen, 71% for mechanical ventilation, and 0% for hospitalization duration. Risk-of-bias assessment identified two studies with low risk and four with unclear risk, indicating acceptable methodological quality. Conclusion This systematic review and meta-analysis evaluated azithromycin efficacy and safety in preventing BPD and reducing mortality in preterm infants. No significant reduction in BPD or mortality was observed with azithromycin compared with placebo. Secondary outcomes, including ventilation duration, supplemental oxygen use, and hospitalization length, showed no improvement. However, heterogeneity among secondary outcomes was moderate to high, and included studies were limited. Systematic Review Registration PROSPERO CRD42024572847.

azithromycinbronchopulmonary dysplasiapreterm infantsneonatal mortality
مقالوصول مفتوح2026

Efficacy and long-term impact of HPV vaccination strategies: A Scoping review of clinical trials and follow-up studies

Pharmacy Practice · مجلد 23 (4) · 1-6

Background: Human papillomavirus (HPV) is a leading cause of cervical cancer and other HPV-related cancers globally. Vaccination against HPV has proven to be a pivotal intervention in reducing the burden of these diseases. However, questions remain regarding long-term efficacy, dosing strategies, and real-world outcomes of HPV vaccines. Objective: We aim to synthesise evidence from randomised controlled trials and long-term follow-up studies on the efficacy, immunogenicity, safety, and real-world impact of HPV vaccines. Methodology: A comprehensive search was conducted in PubMed, Cochrane Library, Embase, Scopus, and Web of Science for studies published in English from 2019 to 2024. Eligible studies included randomised controlled trials and long-term follow-up analyses focusing on HPV vaccine efficacy, dosing regimens, and population-specific outcomes. Data were extracted and synthesised narratively, with findings organised into five thematic areas. Results: Seventeen studies met the inclusion criteria. Findings confirm the high efficacy of HPV vaccines in preventing HPV-related cancers and precancers, with durable immunogenicity observed up to 12 years post-vaccination. Evidence supports the potential of single-dose regimens, which could improve accessibility in resource-limited settings. Real-world data demonstrated significant reductions in HPV-related diseases across diverse populations, reinforcing the global impact of HPV vaccination programs. Conclusion: This review highlights the critical role of HPV vaccines in reducing the burden of HPV-related cancers, with robust efficacy, long-term protection, and favourable safety profiles. The findings underscore the need for continued research into optimised vaccination strategies and the expansion of global vaccination efforts.

HPV vaccinationhuman papillomaviruscervical cancer preventionHPV-associated cancers
مقالوصول مفتوح2026

Efficacy and Safety of Icotrokinra (an Interleukin-23 Inhibitor) in the Management of Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis

JMA Journal · مجلد 9 (5) · 1397-1405

Background: Plaque psoriasis, which is a chronic immune-mediated inflammatory skin condition, significantly reduces patients' quality of life. The cytokine interleukin-23 (IL-23) is a pivotal factor in the development of psoriasis, and icotrokinra is a new oral IL-23 receptor antagonist that has shown potential effectiveness in clinical trials. The main goal of this systematic review and meta-analysis was to assess the effectiveness and safety of icotrokinra in adults and adolescents with moderate-to-severe plaque-type psoriasis. Methods: A comprehensive literature search in PubMed, ScienceDirect, and the Cochrane Library, conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards, identified randomized controlled trials that evaluated daily oral icotrokinra 200 mg versus placebo. The primary outcomes were Psoriasis Area and Severity Index (PASI) 90, Investigator's Global Assessment (IGA) 0/1, and adverse events (AEs) at 16 weeks. Risk ratios with 95% confidence intervals were summed up through a random-effects model. Results: A total of five randomized controlled trials involving 2,755 participants were included. Icotrokinra showed a significant increase in PASI 90, IGA 0/1, IGA 0, and Psoriasis Symptoms and Signs Diary 0 responses compared to placebo. The overall frequency of AEs was similar in both groups, but the rate of treatment discontinuation due to AEs was lower with icotrokinra. Conclusions: Icotrokinra is an effective and well-tolerated oral treatment for moderate-to-severe plaque psoriasis with considerable clinical and patient-reported benefits.

IL-23 inhibitorsplaque psoriasismoderate-to-severe psoriasisefficacy
مراجعةمفتوح (مستودع)2026

Comparative efficacy and safety of chemical peels for acne vulgaris: a systematic review and network metaanalysis of randomized controlled trials

Annals of Middle Eastern Medicine

Background: Chemical peels are widely used for mild-to-moderate acne vulgaris, but comparative evidence is dispersed across small trials and multiple active formulations. This review synthesized the supplied randomized evidence and compared efficacy and tolerability across peel types using network meta-analysis. Methods: PubMed, the Cochrane Library, Scopus, and Web of Science were searched for randomized active-comparator trials of chemical peels for acne vulgaris up to June 2026. Random-effects network meta-analyses used standardized mean differences (SMDs) for continuous outcomes and risk ratios (RRs) for categorical and safety outcomes, each with 95% confidence intervals (CIs). Salicylic acid was the reference treatment, and treatments were ranked using surface under the cumulative ranking curve (SUCRA) values. Results: Twenty-three randomized trials with reported enrollment totaling 1,170 participants were included. Most continuous efficacy comparisons were not statistically significant. Relative to salicylic acid, Jessner's solution was associated with a smaller reduction in papule count (SMD 2.49, 95% CI 1.28 to 3.70) and a smaller reduction in Michaelsson acne score (SMD 1.78, 95% CI 0.41 to 3.16). Salicylic plus mandelic acid ranked highest for good improvement (SUCRA 91.9%), but its RR versus salicylic acid was imprecise (RR 1.96, 95% CI 0.75 to 5.13). Trichloroacetic acid was associated with more erythema than salicylic acid (RR 2.74, 95% CI 1.10 to 6.78). Heterogeneity was substantial for non-inflammatory lesion count, papule count, pustule count, and Michaelsson acne score. Treatment-label fragmentation and undocumented handling of split-face correlations limited confidence in rankings. Conclusion: Our analysis does not establish broad superiority of one chemical peel for acne vulgaris. Salicylic acid performed favorably against Jessner's solution for selected efficacy outcomes and had a lower erythema risk than trichloroacetic acid, but most estimates were imprecise and several networks were heterogeneous. Treatment choice should remain individualized, and the findings require confirmation in rigorously reported head-to-head trials with standardized outcomes.

chemical peelsacnesalicylic acidJessner's solution
مراجعةوصول مفتوح202510استشهاد· Semantic Scholar

Erector spinae plane block versus transversus abdominis plane block for analgesia after cesarean section: a systematic review and meta-analysis

Brazilian Journal of Anesthesiology (English Edition) · مجلد 75 (4) · 844606-844606

Peripheral abdominal nerve blocks are key components of multimodal analgesia, enhancing recovery after cesarean sections. This systematic review and meta-analysis aimed to assess analgesic efficacy of Erector Spinae Plane Block (ESPB) versus Transversus Abdominis Plane Block (TAPB) under ultrasound guidance following Cesarean Section (CS) under spinal anesthesia. A comprehensive search was conducted across PubMed, Scopus, Cochrane Library, and ISI Web of Science to identify relevant trials. The inclusion criteria followed the PICOS framework: Population (women undergoing elective cesarean delivery), Intervention (ESPB), Comparator (TAPB), Outcomes (postoperative pain, opioid consumption, analgesic duration, and satisfaction), and Study Design (randomized controlled trials). Seven RCTs (380-patients) met the inclusion criteria. The ESPB group had significantly lower postoperative pain scores at rest and during movement, reduced 24-hour opioid consumption (MD = -2.62 MME; 95% CI -4.11 to -1.13; p = 0.006), and longer analgesic duration (SMD = 1.77; 95% CI 1.11 to 2.44; p < 0.001) than the TAPB group. Patient satisfaction was also significantly higher in the ESPB group (OR = 4.75; 95% CI 2.26 to 9.99; p < 0.001). While most outcomes demonstrated low heterogeneity, significant variability was observed in analgesic duration (I 2 = 83%), requiring cautious interpretation. The ESP block offers superior pain relief, reduces opioid use, and enhances satisfaction compared to the TAP block in cesarean sections. These findings suggest that the implementation of the ESP block in postoperative analgesia protocols could significantly improve patient outcomes, potentially leading to enhanced recovery and reduced reliance on opioids.

erector spinae plane blocktransversus abdominis plane blockcesarean sectionpostoperative analgesia
مراجعةوصول مفتوح20259استشهاد· Semantic Scholar

Minimally Invasive Approach Versus Traditional Approach for Treating Congenital Diaphragmatic Hernia: A Systematic Review and Meta-Analysis

Cureus · مجلد 17 (1) · e77596-e77596

Congenital diaphragmatic hernia (CDH) is a rare but critical surgical disorder that can be managed using either open or thoracoscopic surgical approaches. However, the optimal approach remains a topic of debate. This study aimed to evaluate the efficacy and safety of thoracoscopic repair compared to open repair in patients with CDH. An extensive literature search was conducted across four databases (PubMed, Web of Science, Scopus, and Cochrane Library) from inception to May 2024, including all relevant studies comparing the two surgical modalities. Key outcomes assessed were hospital stay duration, operation time, mortality, and recurrence. Categorical outcomes were analyzed using the risk ratio (RR) with 95% confidence intervals (CI), while continuous outcomes were analyzed using the mean difference (MD) with 95% CI. Data analysis was performed using Review Manager (RevMan, Version 5.3). A total of 35 studies involving 1,680 individuals with CDH were included in our analysis. The pooled results revealed that thoracoscopic repair was associated with a shorter hospital stay (MD=-6.80, 95% CI [-9.39, -4.21], p< 0.0001) but a longer operation time (MD=23.30, 95% CI [7.22, 39.38], p=0.005) compared to the open approach. Additionally, thoracoscopic repair demonstrated lower mortality rates (RR=0.43, 95% CI [0.24, 0.76], p=0.004) but higher recurrence rates (RR=2.24, 95% CI [1.56, 3.21], p<0.0001) than open repair. Our findings suggest that thoracoscopic repair offers shorter hospital stays and lower mortality rates but involves longer operation times and higher recurrence rates compared to the open approach. These results highlight the need for further large, multicenter, randomized controlled trials to validate our findings and guide clinical decision-making.

congenital diaphragmatic herniathoracoscopic repairopen surgical repairminimally invasive surgery